Straits Times Index
3,272.72 +47.55 (+1.47%) S&P 500
5,072.16 +61.56 (+1.23%) Dow
38,496.80 +256.82 (+0.67%) Nasdaq
15,709.33 +258.02 (+1.67%) Bitcoin USD
66,778.07 +109.77 (+0.16%) CMC Crypto 200
1,436.96 +22.20 (+1.57%)
Ocular Therapeutix, Inc. (OCUL)
| Previous close | 5.07 |
| Open | 5.12 |
| Bid | 5.01 x 100 |
| Ask | 5.06 x 100 |
| Day's range | 4.98 - 5.15 |
| 52-week range | 2.00 - 11.31 |
| Volume | |
| Avg. volume | 2,324,327 |
| Market cap | 746.108M |
| Beta (5Y monthly) | 1.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.02 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.50 |
BenzingaOcular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder
On Thursday, Ocular Therapeutix Inc (NASDAQ:OCUL) announced topline results from the Phase 1 HELIOS study evaluating Axpaxli versus sham control in patients with moderately severe to severe non-proliferative diabetic retinopathy without diabetic macular edema (DME). 6 of 13 (46.2%) patients in the Axpaxli group experienced a 1 or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks, with 2 of the 6 having a 2-step improvement. No patients in the control group showed 1
GlobeNewswireOcular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm No patients in the AXPAXLI group experienced worsening in DRSS compared to 12.5% in the control arm at 40 weeks AXPAXLI was generally well tolerated with no inflammation observed Ocular intends to present the Phase 1 HELIOS study at an upcoming meeting BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, In
- GlobeNewswire
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata Saroj, OD, to Become Development Strategy Consultant Dr. Waheed’s strong industry track record as a CMO and broad expertise in wet AMD and diabetic retinopathy support advancing the Phase 3 AXPAXLI™ program Dr. Kaiser’s vast leadership experience in numerous pivotal trials of approved wet AMD products en
